AbbVie (ABBV) Submits Application for Risankizumab to the EMA
- S&P 500 ends lower after another wild ride
- Apple (AAPL) Tops Q1 EPS by 21c; Revenues Beat
- Visa (V) Shares Up 3% on Strong Q1 Beat
- 'An EV Cash Machine': Tesla (TSLA) Beats on Revenue and Profit But Supply Chain Warning Sends Shares Lower, Analysts Positive and Raise Numbers
- Western Digital (WDC) Shares Dropped 10% Despite Q2 Beat
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
AbbVie (NYSE: ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab (SKYRIZI®, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with moderate to severe active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. The submission is supported by three pivotal Phase 3 studies, ADVANCE, MOTIVATE and FORTIFY.1,2
"Patients with moderate to severe Crohn's disease live with challenging symptoms, such as persistent diarrhea and abdominal pain, impacting their quality of life," said Tom Hudson, senior vice president of research and development, chief scientific officer, AbbVie. "We look forward to working with the regulatory authorities and hope to offer risankizumab as a potential first-in-class treatment option for patients living with this disease."
In the Phase 3 ADVANCE and MOTIVATE induction studies, a significantly greater proportion of patients with Crohn's disease treated with risankizumab IV induction therapy 600 mg achieved both primary endpoints demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo.1
In the Phase 3 FORTIFY maintenance study evaluating Crohn's disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical remission at one year (52 weeks) versus those who were withdrawn from risankizumab (control group).2
No new safety risks were observed in moderate to severe Crohn's disease in the ADVANCE, MOTIVATE and FORTIFY studies compared to the known safety profile of risankizumab.1-6
The use of risankizumab for Crohn's disease is not approved and its safety and efficacy have not been established by regulatory authorities.
Risankizumab (SKYRIZI) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NiSource (NI) Appoints Sondra Barbour and Cassandra Lee to its Board
- Robinhood (HOOD) Reports Q4 Revenues of $363M, EPS of ($0.49)
- NASA Selects Virgin Orbit (VORB) to Provide Future Launch Services Through VADR Contract
Create E-mail Alert Related CategoriesCorporate News, FDA
Related EntitiesTwitter, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!